CClinicalTrials.gg
Active, not recruitingNCT05082038Updated Nov 13, 2023

Mandibular Full-arch Rehabilitation With Internal Hexagonal and Conical Connection Implants

An interventional study of Mandibular partial rehabilitation with IF Tapared implants and Mandibular partial rehabilitation with CF Tapared implants in Edentulous Jaw, sponsored by Neodent. Active, not recruiting at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Neodent · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Nuvo Tapered IF (internal hexagonal connection) and CF (conical connextion) Implants were designed for the the oral functional rehabilitation using dental implants, allowing for treatment of patients with different bone qualities.

The aim of the study is to confirm the long-term safety and clinical performance of implants and abutments of Nuvo IF and CF in daily dental practice setting, by means of prospective collection of clinical data in randomized clinical trial using these devices.

Devices will be used , according to manufacturer indications in the IFU. Patients will be followed for 36 months after implant loading.

Read the detailed description

The study protocol was reviewed and approved by an Ethics Committee (CE) in Brazil. The sample will be prospectively selected and will consist of 18 patients, presenting 18 years of age or more, complete edentulism, who qualify for mandibular rehabilitation by means of full-arch prostheses supported by two Nuvo Tapered IF implants and two Tapered CF implants .Informed consent in writing will be obtained from each patient participating in the study prior to any study related procedure.

Before study site activation, the implants of each patient in the study will be randomly allocated (allocation ratio 1:1), so that each patient receives two implants from each group, on each side of the mandibular arch (Group IF: Tapered Implants with internal hexagonal connection; Group CF: Tapered Implants with conical connection). A blocked randomization list will be generated, where the sequence within block corresponds to the quadrant each group of implants shall be inserted (1:right quadrant; 2: left quadrant). The Randomization List will be kept by the Sponsor in the Trial Master File. Although this study is not blinded, access to the randomization list will not be available to the study centers or to the subjects.

Treatment provided to the subjects will be the responsibility of an appropriately qualified dental practitioners (principal investigator and coinvestigator) to provide the relevant patient care under clinical study conditions, In the mandible, four implants will be placed under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, being two Tapered IF implants on one side and two Tapered CF implants on the other, according to the established by the randomization results. The implants will be placed at preferably in an axial position for the medial implants and distally angled for the distal ones, depending on bone availability.

Immediately after implant placement, the final insertion torque shall be recorded. The selection of the prosthetic component and loading protocol (late or immediate) shall be conducted according to the need of each subject and to the manufacturer's instructions (IFU). Thus, implant immediate loading may be performed (at the discretion of the surgeon) when all implants present primary stability of at least 35 N.cm. Maxillary rehabilitation will be performed by means of confection of muco-supported dentures.

Data concerning the studied variables (mandibular rehabilitation) will be collected following the procedures and assessments plan by fulfilling the Case Report Form (CRF), in the following stages: First visit (Screening); TP - Implants placement; T0 - Implant loading; T6, T12, T24 and T36 - 6, 12, 24 and 36 months, respectively, thereafter.

Panoramic radiographs, lateral cephalometric radiographs and computed tomography (CT) scans will be obtained from the region of interest prior to surgery, for the surgical planning. Additionally, standardized digital periapical radiographs will be taken in a usual daily practice frequency, as determined by the investigator: after implants placement (TP - immediately or within 1 week after implant placement) and during the post-operative stages (T0, T6, T12, T24 and T36) to assess the osseointegration process, changes in peri-implant bone level as well as prosthetic settlement and integrity.

02

Conditions studied

  • Edentulous Jaw

Browse trials for

Keywords

  • dental implants
  • oral rehabilitation
03

In context

Jaw, Edentulous

171 studies on the registry are indexed under Jaw, Edentulous; 24 are open to participants now.

This study's enrollment of 18 is below the median of 33 across 146 interventional studies indexed under Jaw, Edentulous.

Browse Jaw, Edentulous studies →

Lead sponsor

Neodent is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Patients who qualify for mandibular rehabilitation by means of full-arch prostheses supported by two Nuvo Tapered IF implants and two Tapered CF implants

Exclusion criteria

Exclusion Criteria:

Contraindications according to the Instructions for Use of the device will be applied, as follows:

  • Signs of allergy or hypersensitivity to the chemical ingredients of the material: titanium;
  • Presence of acute inflammatory or infectious processes in live tissue;
  • Unsuitable bone volume and/or quality;
  • Systemic complications or diseases such as: bone metabolism disorders, blood clotting disorders, unsuitable healing capacity, insufficient oral hygiene, incomplete jawbone growth, patient uncooperative and not motivated, abuse of drugs or alcohol, psychosis, prolonged functional disorders which resist any treatment with medications, xerostomia, weakened immunological system, diseases which require the use of steroids, endocrinological diseases, pregnancy.

The research does not involve minors, or women who are pregnant or breastfeeding.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Other
    Group IF

    Two Tapered IF implants will be installed in one side of the mandible

    Device: Mandibular partial rehabilitation with IF Tapared implants

  • Other
    Group CF

    Two Tapered IF implants will be installed in the other side of the mandible

    Device: Mandibular partial rehabilitation with CF Tapared implants

Interventions

  • DeviceMandibular partial rehabilitation with IF Tapared implants

    2 IF Tapared Implants (Group IF) on one side of the mandible

  • DeviceMandibular partial rehabilitation with CF Tapared implants

    2 CF Tapared Implants (Group CF) on the other side of the mandible

06

What researchers measure

Primary outcomes

  1. Periimplant bone level change

    Amount of Periimplant bone level change 36 months after loading.

    Time frame: up to 36 months

Secondary outcomes

  1. Implant survival rate

    Survival will be defined as no loss of the implant at each follow-up

    Time frame: up to 36 months

  2. Prosthetic survival

    Prosthetic survival will be assessed as the final prosthesis remaining in situ at each follow-up.

    Time frame: 6, 12, 24 and 36 months

  3. Soft tissue evaluation

    visible plaque index, maginal bleeding index, bleeding on probing, gingival index, keratinized tissue height measurements

    Time frame: up to 36 months

  4. Patient satisfaction

    The Portuguese translation of OHIP-EDENT questionnaire will be used to assess Oral Health Related Quality of Life (OHRQoL), as a measure of patient satisfaction with treatment.

    Time frame: up to 36 months

  5. Clinician satisfaction

    The assessment will be performed by means of a questionnaire using a visual analog scale (VAS) in the form of a 10 cm horizontal line, where 0 (left end) indicates minimum satisfaction and 10 (right end) indicates maximum satisfaction

    Time frame: up to 36 months

  6. Adverse events

    Determined by inquiring with the patient and clinical evaluation

    Time frame: up to 36 months

  7. Device deficiences

    Determined by inquiring with the patient and clinical evaluation

    Time frame: up to 36 months

  8. Implant success rate

    * Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation); * Absence of a recurrent periimplant infection with suppuration (infection is termed recurrent if observed at two or more follow-up visits after the treatment with systemic antibiotics); * Absence of implant mobility on manual palpation; * Absence of any continuous periimplant radiolucency.

    Time frame: up to 36 months

  9. Prosthetic success rate

    Success will be defined as the prosthesis that remained unchanged and did not require any intervention

    Time frame: up to 36 months

07

Study locations

1 site
  • Mattias Sartori Consultoria Em Odontologia
    Bauru, São Paulo, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05082038
Lead sponsor
Neodent
Responsible party
Sponsor
First posted
Oct 18, 2021
Start date
Sep 23, 2021
Primary completion
May 1, 2025 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Nov 13, 2023

Study contacts

Waleska Caldas, PhD
study chair · Neodent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion